Endocrine Abstracts

Background: We have seen an increasing number of carcinoid flare events following PRRT which is a recognised complication of medical/ surgical intervention. Flare events are less severe than carcinoid crisis but require prompt management to avoid patient morbidity and mortality. The rise in this complication is likely due to the complexity and advanced stage of disease at time of therapy commencement. There is very little in the literature about management of this cohort of p...

Approximately 15-20% of phaeochromocytomas and paragangliomas (PPGL) are metastatic. Metastatic spinal cord compression (MSCC) has been reported infrequently. We present three cases of MSCC secondary to metastatic PPGLs. MSCC can occur in patients with PPGLs and should be considered in patients with either spinal symptoms or spinal metastases on imaging. Our series has shown radiotherapy followed by therapeutic MIBG to be effective in treating spinal metastases. Each case shou...

Background: Neuroendocrine tumours (NETs) are rare malignancies; over 60% of primary lesions arise in the gastrointestinal tract and pancreas. Despite several practice-changing clinical trials, uncertainty persists around the most efficacious treatment sequence in patients with advanced well-differentiated gastroenteropancreatic (GEP) NETs, particularly in relation to peptide receptor radionuclide therapy (PRRT). This study aimed to investigate the progression-free survival (P...

Background: Neuroendocrine tumours (NETs) are a rare and heterogeneous group of neoplasms that mainly originate from the gastroenteropancreatic tract (GEP-NETs). The vast majority of NETs tend to overexpress somatostatin receptors (SSTRs), which can be targeted by somatostatin analogues (SSAs). 68Gallium DOTA SSTR peptide positron emission tracer computed tomography (68Ga PET-CT) has emerged as superior to other imaging modalities in identifying SSTRs. Th...